Table 1.

Clinicopathologic significance of XRCC1 expression in PD-L1+ (tumor cells) and PD-LI breast cancers

PD-L1 (tumor cells) and XRCC1 expression
XRCC1+/PD-L1+XRCC1+/PD-L1XRCC1/PD-L1+XRCC1/PD-L1PPadj
(A) Pathologic parameters
Tumor size
 <1 cm39 (69.6%)7 (12.5%)9 (16.1%)1 (1.8%)0.0180.022
 >1–2 cm258 (66.7%)76 (19.6%)37 (9.6%)16 (4.1%)
 >2–5 cm208 (67.1%)35 (11.3%)57 (18.4%)10 (3.2%)
 >5 cm8 (72.7%)1 (9.1%)2 (18.2%)0 (0.0%)
Tumor stage
 1297 (65.4%)87 (19.2%)50 (11.0%)20 (4.4%)0.0009660.00015
 2167 (69.0%)23 (9.5%)47 (19.4%)5 (2.1%)
 352 (74.3%)9 (12.9%)8 (11.4%)1 (1.4%)
Tumor grade
 G180 (71.4%)21 (18.8%)9 (8.0%)2 (1.8%)7.45 × 10−7<0.00001
 G2183 (71.5%)50 (19.5%)14 (5.5%)9 (3.5%)
 G3251 (63.2%048 (12.1%)82 (20.7%)16 (4.0%)
NPI
 ≤3.4145 (70.0%)46 (22.2%)10 (4.8%)6 (2.9%)0.000017<0.00001
 >3.4338 (65.3%)70 (13.5%)90 (17.4%)20 (3.9%)
Mitotic index
 M1 (low; mitoses < 10)172 (72.6%)45 (19.0%)16 (6.8%)4 (1.7%)0.0000290.0001
 M2 (medium; mitoses 10–18)102 (67.5%)23 (15.2%)17 (11.3%)9 (6.0%)
 M3 (high; mitosis >18)231 (64.9%)40 (11.2%)71 (19.9%)14 (3.9%)
Tubule formation
 1 (>75% definite tubule)31 (79.5%)4 (10.3%)4 (10.3%)0 (0.0%)0.1751.925
 2 (10%–75% definite tubule)175 (72.9%)31 (12.9%)26 (10.8%)8 (3.3%)
 3 (<10% definite tubule)299 (64.3%)73 (15.7%)74 (15.9%)19 (4.1%)
Pleomorphism
 1 (Small-regular uniform)7 (63.6%)3 (27.3%)1 (9.1%)0 (0.0%)0.0001080.0002
 2 (Moderate variation)203 (70.7%)54 (18.8%)19 (6.6%)11 (3.8%)
 3 (Marked variation)294 (66.1%)51 (11.5%)84 (18.9%)16 (3.6%)
Tumor type
 IDC-NST313 (66.5%)65 (13.8%)76 (16.1%)17 (3.6%)0.0020.0028
 Tubular103 (74.1%)18 (12.9%)14 (10.0%)4 (2.9%)
 Medullary9 (45.0%)2 (10.0%)7 (35.0%)2 (10.0%)
 ILC48 (67.6%)19 (26.8%)3 (4.2%)1 (1.4%)
 Others4 (44.4%)3 (33.3%)2 (22.2%)0 (0.0%)
 Mixed NST & lobular/special type26 (61.9%)10 (23.8%)3 (7.1%)3 (7.1%)
Her2 overexpression
 No449 (68.1%)100 (15.2%)86 (13.1%)24 (3.6%)0.0220.0242
 Yes64 (64.0%)17 (17.0%)16 (16.0%)3 (3.0%)
ER status
 Negative117 (58.8%)23 (11.6%)46 (23.1%)13 (6.5%)6.9 × 10−7<0.00001
 Positive391 (71.2%)90 (16.4%)55 (10.0%)13 (2.4%)
PR
 Negative185 (60.3%)41 (13.4%)64 (20.8%)17 (5.5%)0.000001<0.00001
 Positive316 (73.1%)69 (16.0%)39 (9.0%)8 (1.9%)

NOTE: Values in bold are statistically significant.

Abbreviations: IDC-NST, invasive ductal carcinoma-non-specific type; ILC, invasive lobular carcinoma.